Camellia sinensis (sinecatechins)
Brand names: Catephen
Camellia sinensis extract (sinecatechins), derived from green tea leaves, is a topical ointment used for the treatment of external anogenital warts.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The catechins, predominantly epigallocatechin gallate, have antioxidant and immunomodulatory properties, although the precise mechanism in clearing genital warts is not fully established.
Prescribing in practice
- Local skin and mucosal reactions such as erythema, itching, burning and pain are very common and expected as part of treatment.
- It should not be applied to open wounds, and the treated area should not be covered with occlusive dressings.
- It may weaken latex condoms and diaphragms, so advise on alternative contraception during use.
Monitoring
Review the treated area periodically for response and to assess the severity of local reactions.
Counselling the patient
- Apply a thin layer to each wart and do not wash off before the next planned application.
- Local redness, itching and discomfort are common and usually tolerable.
- Avoid relying on condoms or diaphragms for protection while using this ointment.
Evidence & guidelines
Sinecatechins ointment is licensed for the treatment of external anogenital warts based on its clinical trial evidence.
Reference: BASHH HPV/warts guideline; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD